comparemela.com

Latest Breaking News On - Leukemia division - Page 1 : comparemela.com

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesDaiichi sankyoSumitomo pharmaMarina konoplevaMichael andreeffDivision of cancer medicineSyndax pharmaceuticalsOncologic drugs advisory committeeUniversity of texas md anderson cancer centerDepartment of leukemiaCancer medicineLeukemia divisionLeukemia research alliance programCancer centerDrugs advisory committeeKura oncology

Challenges in Managing Adverse Events and Unmet Needs in Leukemia

Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.

Gloria leslieJamesk mccloskeyLeukemia divisionJohn theurer cancer centerHackensack university medical centerPeer exchangeHackensack university medicalMash 2023Adverse eventsUnmet needsTreatment sequencingReal world data

The Evolving Treatment Landscape of Leukemia

James K. McCloskey, MD, a specialist in leukemia, discusses how the treatment landscape has changed in recent years.

Jamesk mccloskeyGloria lesliePeer exchangeHackensack university medical centerJohn theurer cancer centerLeukemia divisionHackensack university medical

Recent Data from ASH 2023 in Leukemia

Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.

Jamesk mccloskeyGloria leslieJohn theurer cancer centerPeer exchangeHackensack university medical centerLeukemia divisionHackensack university medical

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis

/PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it.

United statesHong kongUnited kingdomKyongsang buktoSouth koreaHaris aliSrdan verstovsekSelective inhibitor of nuclear exportSection leader for leukemia divisionMd anderson cancer centerCompany sponsored event onClinical research for myeloproliferative neoplasmsAmerican society of hematologyEuropean unionKaryopharm selective inhibitor of nuclear exportNuclear transport inhibition in myelofibrosis

vimarsana © 2020. All Rights Reserved.